BioSpace News Archive

3B Scientific introduced to the global market 3B SMART ANATOMY, a new generation of anatomical models. 3B SMART ANATOMY is designed to close the gap between analog and digital learning.

GetInsured, a market leader in individual health insurance e-commerce, today announced it is the first company to pass the official Center for Medicare & Medicaid Services (CMS) audit and has been approved to offer Phase 3 Enhanced Direct Enrollment (EDE) technology.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019, after the close of the financial markets.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the 39th Annual Canaccord Genuity Growth Conference at 10:30 a.m. ET on Wednesday, August 7, 2019 in Boston, MA.

LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlusTM series of antibodies.

Regulus Therapeutics Inc. announced a program update for RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Grant expands BioGenerator Labs and Commercialization Resources

This not only marks a milestone for WuXi STA on running a continual state of regulatory readiness, with real time GMP monitoring and an ingrained internal quality culture, but also shows its commitment on providing integrated R&D and manufacturing services with the highest quality standard for customers.

Gain Therapeutics SA announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.

JNDA Submission Represents First Regulatory Submission for Marketing Approval of Vadadustat